Chloroquine

Chloroquine

Chemical compound and drug used to treat malaria, autoimmune disease and other conditions

All edits

Edits on 18 May, 2020
Golden AI"Wikidata import from WikidataImport1"
Golden AI edited on 18 May, 2020 6:43 pm
Edits made to:
Infobox (+1 properties)

Infobox

Wikidata entity ID
Q422438
Edits on 10 April, 2020
Jude Gomila
Jude Gomila edited on 10 April, 2020 2:28 am
Edits made to:
Article

Article

Edits on 7 April, 2020
Neelam Jhaveri
Neelam Jhaveri approved a suggestion from Golden's AI on 7 April, 2020 3:58 am
Edits made to:
Article (+16/-16 characters)

Article

A randomized controlled trial conducted by researchers at Wuhan UniversityWuhan University including 62 patients found that time to clinical recovery, based on clinical characteristics and radiological results 5 days after treatment, was significantly shortened in the hydroxychloroquine group.

Edits on 6 April, 2020
Meredith Hanel
Meredith Hanel edited on 6 April, 2020 8:47 pm
Edits made to:
Article (+9/-12 characters)

Article

A randomized controlled trial conducted by researchers at Wuhan University includedincluding 62 patients and found that time to clinical recovery, based on clinical characteristics and radiological results 5 days after treatment, was significantly shortened in the hydroxychloroquine group.

Meredith Hanel
Meredith Hanel edited on 6 April, 2020 8:40 pm
Edits made to:
Article (+442 characters)

Article

As of March 26, 2020 the NIH Clinical Trials database showed 18 clinical trials listing hydroxychloroquine as an intervention. Hydroxychloroquine alone and in combination with the the antibiotic azithromycin (aka Zithromas or Azithrocin) have reported early evidence of being effective in treating COVID-19 in preliminary results in a small study on 30 patients in France, led by Didier Raoult. Controls in the study were patients who refused treatment, had exclusion criteria and patients in other medical centers that did not receive hydroxychloroquine. According to the paper Azithromycin was given to some patients to prevent bacterial super-infection. Azithromycin is also known to have immunomodulatory effects.It is not clear if differences between patients that received hydroxychoroquine alone and the combination therapy may be due to differences in the patient's viral load between the two groups. Subsequent results from Raoult's group have been released where all patients were given the hydroxychloroquine and azithromycin combination.

...

A randomized controlled trial conducted by researchers at Wuhan University included 62 patients and found that time to clinical recovery, based on clinical characteristics and radiological results 5 days after treatment, was significantly shortened in the hydroxychloroquine group.

Meredith Hanel
Meredith Hanel edited on 6 April, 2020 8:01 pm
Edits made to:
Article (+39/-132 characters)

Article

As of March 26, 2020 the NIH Clinical Trials database showed 18 clinical trials listing hydroxychloroquine as an intervention. Hydroxychloroquine alone and in combination with the the antibiotic azithromycin (aka Zithromas or Azithrocin) have reported early evidence of being effective in treating COVID-19 in preliminary results in a small study on 30 patients in France, led by Didier Raoult. The trial lacks a control group that did not receive hydroxychloroquine. According to the paper Azithromycin was given to some patients to prevent bacterial super-infection. Azithromycin is also known to have immunomodulatory effects.It is not clear if differences between patients that received hydroxychoroquine alone and the combination therapy may be due to differences in the patient's viral load between the two groups. Subsequent results from Raoult's group have been released where all patients were given the hydroxychloroquine and azithromycin combination.

...

TheA firstrandomized controlled study, a randomized trial comparing patients treated with hydroxychloroquine and a control group with 30 patients performed by researchers at Fudan University, Shanghai. This study led by LU Hongzhou found no difference between the hydroxychloroquine and control groups in the time it took to achieve negative throat swabs for the virus and normalization of body temperature and radiological progression by CT imaging. The authors noted that a larger sample size was needed to assess the effects of hydroxychloroquine on COVID-19.

Edits on 3 April, 2020
Aime Anne Nisay
Aime Anne Nisay approved a suggestion from Golden's AI on 3 April, 2020 11:49 am
Edits made to:
Article (+8/-8 characters)

Article

The first controlled study, a randomized trial comparing patients treated with hydroxychloroquine and a control group with 30 patients performed by researchers at Fudan University, ShanghaiShanghai. This study led by LU Hongzhou found no difference between the hydroxychloroquine and control groups in time to achieve negative throat swabs for the virus and normalization of body temperature and radiological progression by CT imaging. The authors noted that a larger sample size was needed to assess the effects of hydroxychloroquine on COVID-19.

Neelam Jhaveri
Neelam Jhaveri approved a suggestion from Golden's AI on 3 April, 2020 7:12 am
Edits made to:
Article (+16/-16 characters)

Article

The first controlled study, a randomized trial comparing patients treated with hydroxychloroquine and a control group with 30 patients performed by researchers at Fudan UniversityFudan University, Shanghai. This study led by LU Hongzhou found no difference between the hydroxychloroquine and control groups in time to achieve negative throat swabs for the virus and normalization of body temperature and radiological progression by CT imaging. The authors noted that a larger sample size was needed to assess the effects of hydroxychloroquine on COVID-19.

Neelam Jhaveri
Neelam Jhaveri approved a suggestion from Golden's AI on 3 April, 2020 6:45 am
Edits made to:
Article (+13/-13 characters)

Article

As of March 26, 2020 the NIH Clinical Trials database showed 18 clinical trials listing hydroxychloroquine as an intervention. Hydroxychloroquine alone and in combination with the the antibiotic azithromycin (aka Zithromas or Azithrocin) have reported early evidence of being effective in treating COVID-19 in preliminary results in a small study on 30 patients in France, led by Didier RaoultDidier Raoult. The trial lacks a control group that did not receive hydroxychloroquine. According to the paper Azithromycin was given to some patients to prevent bacterial super-infection. Azithromycin is also known to have immunomodulatory effects.It is not clear if differences between patients that received hydroxychoroquine alone and the combination therapy may be due to differences in the patient's viral load between the two groups. Subsequent results from Raoult's group have been released where all patients were given hydroxychloroquine and azithromycin.

Edits on 2 April, 2020
Meredith Hanel
Meredith Hanel edited on 2 April, 2020 1:27 pm
Edits made to:
Article (+830/-10 characters)

Article

Chloroquine has been reported to be an effective antiviral therapeutic against COVID-19 in treatments done in China and South Korea, with clinical trialtrials ongoing as of March 2020. Treatment with chloroquine tablets was reported to show favorable outcomes such as faster time to recover and shorter hospital stay in people with COVID-19 infections. Laboratory research from the US CDC shows chloroquine also has potential to treat prophylactically. Chloroquine is being investigated to treat COVID-19 in the form of chloroquine phosphate or hydroxychloroquine sulfate which are sometimes referred to as chloroquine and hydroxychloroquine respectively.

...

As of March 26, 2020 the NIH Clinical Trials database showed 18 clinical trials listing hydroxychloroquine as an intervention. Hydroxychloroquine alone and in combination with the the antibiotic azithromycin (aka Zithromas or Azithrocin) have shownreported early evidence of being effective in treating COVID-19 in preliminary results in a small study on 30 patients in France, led by Didier Raoult. The trial lacks a control group that did not receive hydroxychloroquine. According to the paper Azithromycin was given to some patients to prevent bacterial super-infection. Azithromycin is also known to have immunomodulatory effects.It is not clear if differences between patients that received hydroxychoroquine alone and the combination therapy may be due to differences in the patient's viral load between the two groups. Subsequent results from Raoult's group have been released where all patients were given hydroxychloroquine and azithromycin.

The first controlled study, a randomized trial comparing patients treated with hydroxychloroquine and a control group with 30 patients performed by researchers at Fudan University, Shanghai. This study led by LU Hongzhou found no difference between the hydroxychloroquine and control groups in time to achieve negative throat swabs for the virus and normalization of body temperature and radiological progression by CT imaging. The authors noted that a larger sample size was needed to assess the effects of hydroxychloroquine on COVID-19.

Mechanism for antiviral activity

Page 1 of 2
Edits on 27 March, 2020
Neelam Jhaveri
Neelam Jhaveri approved a suggestion from Golden's AI on 27 March, 2020 7:28 am
Edits made to:
Article (+6/-6 characters)

Article

As of March 26, 2020 the NIH Clinical Trials database showed 18 clinical trials listing hydroxychloroquine as an intervention. Hydroxychloroquine alone and in combination with the the antibiotic azithromycin (aka Zithromas or Azithrocin) have shown early evidence of being effective in treating COVID-19 in preliminary results in a small study on 30 patients in FranceFrance. Azithromycin was given to some patients to prevent bacterial super-infection. Azithromycin is also known to have immunomodulatory effects.It is not clear if differences between patients that received hydroxychoroquine alone and the combination therapy may be due to differences in the patient's viral load between the two groups.

Edits on 26 March, 2020
Meredith Hanel
Meredith Hanel edited on 26 March, 2020 8:38 pm
Edits made to:
Article (+69/-66 characters)

Article

As of March 26, 2020 the NIH Clinical Trials database showed 18 clinical trials listing hydroxychloroquine as an intervention. Hydroxychloroquine alone and in combination with the the antibiotic azithromycin (aka Zithromas or Azithrocin) have shown early evidence of being effective in treating COVID-19 in preliminary results in a small study on 30 patients in France. Azithromycin was given to some patients to prevent bacterial super-infection. At this time thereAzithromycin is noalso otherknown datato onhave useimmunomodulatory ofeffects.It azithromycinis onnot coronavirusesclear andif differences between patients that received hydroxychoroquine alone and the combination therapy may be due to differences in the patient's viral load between the two groups.

Meredith Hanel
Meredith Hanel edited on 26 March, 2020 3:16 pm
Edits made to:
Article (+78 characters)

Article

As of March 26, 2020 the NIH Clinical Trials database showed 18 clinical trials listing hydroxychloroquine as an intervention. Hydroxychloroquine alone and in combination with the antibiotic azithromycin (aka Zithromas or Azithrocin) have shown early evidence of being effective in treating COVID-19 in preliminary results in a small study on 30 patients in France. Azithromycin was given to some patients to prevent bacterial super-infection. At this time there is no other data on use of azithromycin on coronaviruses and differences between patients that received hydroxychoroquine alone and the combination therapy may be due to differences in the patient's viral load between the two groups.

Meredith Hanel
Meredith Hanel edited on 26 March, 2020 3:02 pm
Edits made to:
Article (+281/-80 characters)

Article

As of March 26, 2020 the NIH Clinical Trials database showed 18 clinical trials listing hydroxychloroquine as an intervention. AHydroxychloroquine alone and in combination of hydroxychloroquine andwith the antibiotic azithromycin (aka Zithromas or Azithrocin) have shown early evidence of being effective in treating COVID-19 in preliminary results in a small study on 30 patients in France. HydroxychloroquineAt wasthis effectivetime there is no other data on ituse ownof butazithromycin noton ascoronaviruses effectiveand asdifferences between patients that received hydroxychoroquine alone and the combination therapy may be due to differences in the patient's viral load between the two groups.

Meredith Hanel
Meredith Hanel edited on 26 March, 2020 2:37 pm
Edits made to:
Article (+417/-126 characters)

Article

Chloroquine has been reported to be an effective antiviral therapeutic against COVID-19 in treatments done in China and South Korea, with clinical trial ongoing as of March 2020. Treatment with chloroquine tablets was reported to show favorable outcomes such as faster time to recover and shorter hospital stay in people with COVID-19 infections. Laboratory research from the US CDC shows chloroquine also has potential to treat prophylactically. Chloroquine is being investigated to treat COVID-19 in the form of chloroquine phosphate or hydroxychloroquine sulfate which are sometimes referred to as chloroquine and hydroxychloroquine respectively. As of March 26, 2020 the NIH Clinical Trials database showed 18 clinical trials listing hydroxychloroquine as an intervention.

As of March 26, 2020 the NIH Clinical Trials database showed 18 clinical trials listing hydroxychloroquine as an intervention. A combination of hydroxychloroquine and the antibiotic azithromycin (aka Zithromas or Azithrocin) have shown early evidence of being effective in treating COVID-19 in a small study on 30 patients in France. Hydroxychloroquine was effective on it own but not as effective as the combination.

Meredith Hanel
Meredith Hanel edited on 26 March, 2020 2:25 pm
Edits made to:
Timeline (+2 events) (+222 characters)
Article (+127 characters)

Article

Chloroquine has been reported to be an effective antiviral therapeutic against COVID-19 in treatments done in China and South Korea, with clinical trial ongoing as of March 2020. Treatment with chloroquine tablets was reported to show favorable outcomes such as faster time to recover and shorter hospital stay in people with COVID-19 infections. Laboratory research from the US CDC shows chloroquine also has potential to treat prophylactically. Chloroquine is being investigated to treat COVID-19 in the form of chloroquine phosphate or hydroxychloroquine sulfate which are sometimes referred to as chloroquine and hydroxychloroquine respectively. As of March 26, 2020 the NIH Clinical Trials database showed 18 clinical trials listing hydroxychloroquine as an intervention.

Timeline

March 18, 2020

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

February 4, 2020

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Meredith Hanel
Meredith Hanel edited on 26 March, 2020 1:06 pm
Edits made to:
Article (+39/-39 characters)

Article

Chloroquine has been reported to be an effective antiviral therapeutic against COVID-19 in treatments done in China and South Korea, with clinical trial ongoing as of March 2020. Treatment with chloroquine tablets was reported to show favorable outcomes such as faster time to recover and shorter hospital stay in people with COVID-19 infections. Laboratory research from the US CDC shows chloroquine also has potential to treat prophylactically. Chloroquine is being investigated to treat COVID-19 in the form of chloroquine phosphatechloroquine phosphate or hydroxychloroquinehydroxychloroquine sulfate which are sometimes referred to as chloroquine and hydroxychloroquine respectively.

Edits on 19 March, 2020
Neelam Jhaveri
Neelam Jhaveri approved a suggestion from Golden's AI on 19 March, 2020 7:33 am
Edits made to:
Article (+11/-11 characters)

Article

Chloroquine has been reported to be an effective antiviral therapeutic against COVID-19 in treatments done in China and South KoreaSouth Korea, with clinical trial ongoing as of March 2020. Treatment with chloroquine tablets was reported to show favorable outcomes such as faster time to recover and shorter hospital stay in people with COVID-19 infections. Laboratory research from the US CDC shows chloroquine also has potential to treat prophylactically. Chloroquine is being investigated to treat COVID-19 in the form of chloroquine phosphate or hydroxychloroquine sulfate which are sometimes referred to as chloroquine and hydroxychloroquine respectively.

Aime Anne Nisay
Aime Anne Nisay approved a suggestion from Golden's AI on 19 March, 2020 7:20 am
Edits made to:
Article (+5/-5 characters)

Article

Chloroquine has been reported to be an effective antiviral therapeutic against COVID-19 in treatments done in ChinaChina and South Korea, with clinical trial ongoing as of March 2020. Treatment with chloroquine tablets was reported to show favorable outcomes such as faster time to recover and shorter hospital stay in people with COVID-19 infections. Laboratory research from the US CDC shows chloroquine also has potential to treat prophylactically. Chloroquine is being investigated to treat COVID-19 in the form of chloroquine phosphate or hydroxychloroquine sulfate which are sometimes referred to as chloroquine and hydroxychloroquine respectively.

Aime Anne Nisay
Aime Anne Nisay approved a suggestion from Golden's AI on 19 March, 2020 6:46 am
Edits made to:
Article (+10/-10 characters)

Article

Chloroquine has been reported to be an effective antiviral therapeutic against COVID-19 in treatments done in China and South Korea, with clinical trial ongoing as of March 2020. Treatment with chloroquine tablets was reported to show favorable outcomes such as faster time to recover and shorter hospital stay in people with COVID-19 infections. LaboratoryLaboratory research from the US CDC shows chloroquine also has potential to treat prophylactically. Chloroquine is being investigated to treat COVID-19 in the form of chloroquine phosphate or hydroxychloroquine sulfate which are sometimes referred to as chloroquine and hydroxychloroquine respectively.

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.